← back to search

Andreas Faldum

University of Münster · DE
🔎 Find collaborators in Neurology · Genetics →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Neurology · Genetics
Research interest
Research interests include Neuroblastoma Research and Treatments, Glioma Diagnosis and Treatment, Cancer, Hypoxia, and Metabolism, and Pituitary Gland Disorders and Treatments.
h-index
43
citations
9,295
works
279
NIH funding
primary concept
Medicine
email

Recent publications

The HIT Network for Children and Adolescents With CNS Tumors Facilitates Improvements of Diagnostic Assessments, Multimodal Treatments, Individual Counseling, and Research in Germany, Austria, and Switzerland
Pediatric Blood & Cancer 2026cited by 0position: middledoi
Geriatric-Typical Characteristic Complexes Predict Short-Term Outcome of Proximal Humeral Fractures in Geriatric Patients.
2026cited by 0position: contributordoi
Temozolomide-based radio-chemotherapy for newly diagnosed pediatric high-grade gliomas (HIT-HGG-2007): A prospective, multicenter, single-arm, phase II trial
EJC Paediatric Oncology 2025cited by 2position: middledoi
Temozolomide-based radio-chemotherapy for newly diagnosed pediatric high-grade gliomas (HIT-HGG-2007): A prospective, multicenter, single-arm, phase II trial
EJC Paediatric Oncology 2025cited by 2position: contributordoi
The HIT-network for children and adolescents with CNS tumors facilitates improvements of diagnostic assessments, multimodal treatments, individual counselling, and research in Germany, Austria, and Switzerland
2025cited by 1position: middledoi
Developing an advanced risk stratification model for pediatric intracranial ependymoma based on the prospective trial E-HIT2000 and subsequent registries
Neuro-Oncology 2025cited by 1position: middledoi
Neuropsychological late effects in young children with medulloblastoma: A longitudinal analysis after 5 and 15 years from the HIT-SKK-’87/’92 studies
Neuro-Oncology Practice 2025cited by 0position: middledoi
Characterizing Overall Survival of Patients with Acute Myeloid Leukemia: A Competing Risk Analysis of SEER Data Covering 46 Years.
2025cited by 0position: contributordoi
EPEN-14. MOLECULAR MARKERS AND PREDICTORS OF OUTCOME FOR PAEDIATRIC INTRACRANIAL EPENDYMOMA IN THE PROSPECTIVE, MULTICENTRE E-HIT2000 TRIAL AND SUBSEQUENT HIT-REGISTRIES: A POOLED ANALYSIS OF 244 PATIENTS
Neuro-Oncology 2024cited by 2position: middledoi
Increased complication rates of salvage reverse total shoulder arthroplasty (RTSA) after failed locked plate fixation compared with primary RTSA in the treatment of proximal humeral fractures in elderly patients
Journal of Shoulder and Elbow Surgery 2023cited by 12position: contributordoi
Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
Clinical Cancer Research 2023cited by 11position: middledoi
Treatment Reality of Proximal Humeral Fractures in the Elderly-Trending Variants of Locking Plate Fixation in Germany.
2023cited by 10position: contributordoi
Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial.
2023cited by 5position: contributordoi
Study Protocol S1 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
2023cited by 0position: contributordoi
Supplementary Figure S1 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
2023cited by 0position: contributordoi
Study Protocol S1 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
2023cited by 0position: contributordoi
Data from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
2023cited by 0position: contributordoi
Supplementary Table S4 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
2023cited by 0position: contributordoi
Supplementary Table S6 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
2023cited by 0position: contributordoi
Supplementary Data S2 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
2023cited by 0position: contributordoi
Supplementary Table S4 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
2023cited by 0position: contributordoi
Supplementary Data S2 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
2023cited by 0position: contributordoi
Supplementary Statistics S1 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
2023cited by 0position: contributordoi
Supplementary Statistics S1 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
2023cited by 0position: contributordoi
Supplementary Table S5 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
2023cited by 0position: contributordoi
Supplementary Figure S4 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
2023cited by 0position: contributordoi
Supplementary Table S5 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
2023cited by 0position: contributordoi
Supplementary Table S2 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
2023cited by 0position: contributordoi
Supplementary Data S1 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
2023cited by 0position: contributordoi
Supplementary Table S3 from Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
2023cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 9 papers (2019–2026)Stefan Rutkowski · Universität Hamburg8 papers (2014–2025)Karsten Spiekermann · German Cancer Research Center7 papers (2013–2020)Utz Krug · University Hospital Münster7 papers (2013–2025)Wolfgang E. Berdel · Klinik für Schlafmedizin7 papers (2013–2020)Monika Warmuth‐Metz · Universitätsklinikum Würzburg7 papers (2012–2025)Torsten Pietsch · German Center for Neurodegenerative Diseases7 papers (2014–2022)Jan Braess · Ludwig-Maximilians-Universität München7 papers (2013–2020)Wolfgang Hiddemann · Deutsche Forschungsgemeinschaft7 papers (2013–2020)Maja Rothenberg‐Thurley · TUM Klinikum6 papers (2015–2020)Robert Kwiecien · Johannes Gutenberg University Mainz6 papers (2014–2022)Klaus H. Metzeler · Krankenhaus Barmherzige Brüder6 papers (2015–2020)Stefan M. Pfister · Université du Québec6 papers (2014–2022)Rolf‐Dieter Kortmann · University Medical Center6 papers (2012–2025)Nikola P. Konstandin · LMU Klinikum6 papers (2015–2020)Stefan K. Bohlander · University of Auckland6 papers (2015–2020)Katja von Hoff · Aarhus University6 papers (2014–2025)Martin Mynarek · Universität Hamburg6 papers (2014–2025)Bianka Ksienzyk · Munich Leukemia Laboratory (Germany)6 papers (2015–2020)Tobias Herold · German Cancer Research Center6 papers (2015–2020)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Neurology · Genetics →